Table 4.
Inhibition of cancer cell growth by combretastatin D-2 (2) and prodrug salts [55].
| GI50 mg·mL−1 (molar concentration)a |
||||||
|
| ||||||
| pancreas | breast | brain | lung | colon | prostate | |
|
| ||||||
| 2 | 4.8 (16.2 μM) |
6.6 (22.3 μM) |
4.7 (15.9 μM) |
6.0 (20.2 μM) |
>10 (33.7 μM) |
2.7 (9.1 μM) |
| 28 | 7.3 (23.5 μM) |
0.83 (2.7 μM) |
2.2 (7.1 μM) |
6.6 (21.3 μM) |
9.4 (30.3 μM) |
5.6 (18 μM) |
| 184 | 22.1 (52.6 μM) |
30.5 (72.6 μM) |
36.3 (86.4 μM) |
13.3 (31.6 μM) |
25.5 (60.7 μM) |
18.2 (43.3 μM) |
| 185 | 40.1 (88.6 μM) |
34.5 (76.2 μM) |
45.2 (99.9 μM) |
27.8 (61.4 μM) |
40.6 (89.7 μM) |
14.4 (31.2 μM) |
| 186 | 35.9 (92.5 μM) |
26.1 (67.2 μM) |
37.9 (97.6 μM) |
14.4 (31.1 μM) |
27.5 (70.8 μM) |
4.3 (11.1 μM) |
| 187 | >10 (>18 μM) |
>10 (>18 μM) |
>10 (>18 μM) |
>10 (>18 μM) |
>10 (>18 μM) |
>10 (>18 μM) |
aApproximated values of molar concentration after conversion.